COVID-19与流感肺炎插管患者的早期细菌鉴定:欧洲多中心比较临床试验
该多中心回顾性欧洲队列纳入36个ICU的1050例(SARS-CoV-2组568例、流感组482例)有创机械通气>48小时的成人肺炎患者,比较插管后48小时内细菌鉴定(气道吸引物、BAL、血培养阳性或肺炎链球菌/军团菌尿抗原阳性)的患病率。SARS-CoV-2组细菌鉴定患病率显著低于流感组(9.7% vs 33.6%;未调整OR 0.21,95%CI 0.15-0.30;调整OR 0.23,95%CI 0.16-0.33;P<0.0001)。革兰阳性球菌分别占SARS-CoV-2和流感合并感染的58%和72%。在SARS-CoV-2组,细菌鉴定与28天死亡率调整HR 1.57(95%CI 1.01-2.44;P=0.043)相关,但两组间该效应异质性无显著差异。
要点
- 插管后48小时内细菌鉴定在SARS-CoV-2肺炎显著低于流感肺炎(9.7% vs 33.6%;未调整OR 0.21,95%CI 0.15-0.30;调整OR 0.23,95%CI 0.16-0.33;P<0.0001)。
- 细菌鉴定与SARS-CoV-2组28天死亡率升高相关(调整HR 1.57,95%CI 1.01-2.44;P=0.043)。
- 两组细菌鉴定对死亡影响的异质性无显著差异,提示合并感染对死亡率的影响在SARS-CoV-2与流感间无差异。
- 革兰阳性球菌占SARS-CoV-2合并感染的58%、流感合并感染的72%。
- 研究为多中心回顾性欧洲队列,纳入36个ICU的1050例有创机械通气>48小时成人患者。
适用人群与场景
- 36个ICU的成人患者,ICU入院时诊断为SARS-CoV-2肺炎或流感肺炎,且接受有创机械通气>48小时。
诊断标准与关键阈值
- 细菌鉴定定义:插管后48小时内气道吸引物、BAL、血培养阳性,或肺炎链球菌/军团菌尿抗原检测阳性。
研究设计与关键结果
- 多中心回顾性欧洲队列,纳入36个ICU共1050例患者(SARS-CoV-2组568例,流感组482例)。
- 细菌鉴定患病率SARS-CoV-2组9.7% vs 流感组33.6%;未调整OR 0.21(95%CI 0.15-0.30);调整OR 0.23(95%CI 0.16-0.33);P<0.0001。
- 革兰阳性球菌占SARS-CoV-2合并感染的58%,占流感合并感染的72%。
- 细菌鉴定与SARS-CoV-2组28天死亡率升高相关(调整HR 1.57,95%CI 1.01-2.44;P=0.043)。
- 两组间细菌鉴定相关结局的异质性无显著差异,提示合并感染对死亡率的影响在SARS-CoV-2与流感间无差异。
证据类型、等级与局限
- 证据类型:多中心回顾性欧洲队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在插管SARS-CoV-2肺炎患者中,早期细菌鉴定患病率低于流感肺炎患者(9.7% vs 33.6%),细菌鉴定与28天死亡率升高相关(调整HR 1.57,95%CI 1.01-2.44;P=0.043)。
指南或共识出处
- 临床试验注册号NCT04359693(www.clinicaltrials.gov)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Early empirical antimicrobial treatment is frequently prescribed to critically ill patients with coronavirus disease (COVID-19) based on Surviving Sepsis Campaign guidelines.Objectives: We aimed to determine the prevalence of early bacterial identification in intubated patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia, as compared with influenza pneumonia, and to characterize its microbiology and impact on outcomes.Methods: A multicenter retrospective European cohort was performed in 36 ICUs. All adult patients receiving invasive mechanical ventilation >48 hours were eligible if they had SARS-CoV-2 or influenza pneumonia at ICU admission. Bacterial identification was defined by a positive bacterial culture within 48 hours after intubation in endotracheal aspirates, BAL, blood cultures, or a positive pneumococcal or legionella urinary antigen test.Measurements and Main Results: A total of 1,050 patients were included (568 in SARS-CoV-2 and 482 in influenza groups). The prevalence of bacterial identification was significantly lower in patients with SARS-CoV-2 pneumonia compared with patients with influenza pneumonia (9.7 vs. 33.6%; unadjusted odds ratio, 0.21; 95% confidence interval [CI], 0.15-0.30; adjusted odds ratio, 0.23; 95% CI, 0.16-0.33; P < 0.0001). Gram-positive cocci were responsible for 58% and 72% of coinfection in patients with SARS-CoV-2 and influenza pneumonia, respectively. Bacterial identification was associated with increased adjusted hazard ratio for 28-day mortality in patients with SARS-CoV-2 pneumonia (1.57; 95% CI, 1.01-2.44; P = 0.043). However, no significant difference was found in the heterogeneity of outcomes related to bacterial identification between the two study groups, suggesting that the impact of coinfection on mortality was not different between patients with SARS-CoV-2 and influenza.Conclusions: Bacterial identification within 48 hours after intubation is significantly less frequent in patients with SARS-CoV-2 pneumonia than patients with influenza pneumonia.Clinical trial registered with www.clinicaltrials.gov (NCT04359693).
参考来源
- Rouzé A, Martin-Loeches I, Povoa P, et al. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. Am J Respir Crit Care Med. 2021. PMID: 34038699. doi:10.1164/rccm.202101-0030OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。